Equities analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will report earnings of ($0.44) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.28). Heron Therapeutics reported earnings per share of ($0.97) during the same quarter last year, which suggests a positive year over year growth rate of 54.6%. The firm is expected to announce its next earnings results on Tuesday, February 26th.
On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.34) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($2.18). For the next year, analysts anticipate that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.44) to $0.03. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The business had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. During the same quarter last year, the company earned ($0.77) earnings per share. The firm’s revenue was up 130.9% compared to the same quarter last year.
In related news, Director Kevin C. Tang sold 2,695,000 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total transaction of $96,346,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kimberly Manhard sold 6,000 shares of the stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $32.07, for a total value of $192,420.00. Following the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at $192,420. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,701,494 shares of company stock valued at $96,553,796. 16.20% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of HRTX. Cubist Systematic Strategies LLC acquired a new position in Heron Therapeutics during the second quarter valued at approximately $151,000. Jefferies Group LLC acquired a new position in Heron Therapeutics during the third quarter valued at approximately $202,000. Verition Fund Management LLC acquired a new position in Heron Therapeutics during the third quarter valued at approximately $208,000. Pacer Advisors Inc. acquired a new position in Heron Therapeutics during the third quarter valued at approximately $223,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Heron Therapeutics during the third quarter valued at approximately $224,000.
NASDAQ:HRTX opened at $27.88 on Friday. The stock has a market cap of $2.18 billion, a P/E ratio of 7.64 and a beta of 1.48. Heron Therapeutics has a 52-week low of $15.00 and a 52-week high of $42.90.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.